Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
复制标题
DOI：
10.1186/1471-2377-13-82
复制
发表时间：
2013-07-11
期刊：
影响因子：
2.6
通讯作者：
Sánchez-Matienzo D
中科院分区：
文献类型：
--
作者：
Muñoz D;Escartín A;Dapena D;Coret F;Fernández-Uría D;Pérez D;Casanova B;Guijarro-Castro C;Munteis E;del-Campo Amigo M;Pego R;Calles C;García-Rey C;Monsalve N;Sánchez-Matienzo D
本研究的目的是在既往未接受过IFN β治疗的复发缓解型多发性硬化症患者中，在治疗滴定期间，将体重指数或生物标志物与皮下注射IFN β-1a的常见不良事件（AE）频率相关联。84例患者（66.3%女性）在8周内随访，25.3%超重，14.5%肥胖。在整个研究期间，生物标志物稳定增加，β2-微球蛋白增加45.3%，多聚腺苷酸合成酶-1增加262.8%，新蝶呤增加92.8%。总体AE报告不随剂量或治疗持续时间而变化。BMI不能预测AE风险增加。生物标志物也不区分任何AE的频率。
This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN β-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naïve to IFN β. Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and 14.5% were obese. Biomarkers steadily increased during all study period by 45.3% for β2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment duration. BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of any AE either.
登录
查看更多内容
影响因子：
9.9
作者：
Marrie, R. A.;Horwitz, R.;Vollmer, T.
通讯作者：
Vollmer, T.
影响因子：
3.3
作者：
Bagnato, F;Durastanti, V;Millefiorini, E
通讯作者：
Millefiorini, E
影响因子：
3.3
作者：
Rothuizen, LE;Buclin, T;Biollaz, J
通讯作者：
Biollaz, J
影响因子：
14.5
作者：
Giovannoni, G;Lai, M;Thompson, EJ
通讯作者：
Thompson, EJ
影响因子：
5.1
作者：
Bagnato, F;Zivadinov, R;Millefiorini, E
通讯作者：
Millefiorini, E